Thongprasert,S., Tinmanee,S., & Permsuwan,U. (2015). Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective. Wiley-Blackwell.
Chicago Style CitationThongprasert,S., Tinmanee,S, and Permsuwan,U. Cost-utility and Budget Impact Analyses of Gefitinib in Second-line Treatment for Advanced Non-small Cell Lung Cancer From Thai Payer Perspective. Wiley-Blackwell, 2015.
MLA引文Thongprasert,S., Tinmanee,S, and Permsuwan,U. Cost-utility and Budget Impact Analyses of Gefitinib in Second-line Treatment for Advanced Non-small Cell Lung Cancer From Thai Payer Perspective. Wiley-Blackwell, 2015.
警告：這些引文格式不一定是100％准確.